



RELEASE: January 31, 2006

C o m m u n i q u é

The PMPRB to Hold a Public Hearing into the Price of Risperdal Consta

OTTAWA, **January 31, 2006**: The Patented Medicine Prices Review Board will hold a public hearing on June 7, 2006, in the matter of Janssen-Ortho Inc. ("Janssen-Ortho") and the price of the medicine Risperdal Consta. A pre-hearing conference will also be held April 21, 2006.

The purpose of the hearing is to determine whether, under sections 83 and 85 of the *Patent Act*, Janssen-Ortho

- is selling or has sold the medicine known as "Risperdal Consta" in any market in Canada at a price that, in the Board's opinion, is or was excessive; and,
- if so, what order, if any, should be made.

Health Canada issued a Notice of Compliance for Risperdal Consta 25 mg, 37.5 mg, and 50 mg vials (DINs 02255707, 02255723, and 02255758) on July 16, 2004. Janssen-Ortho began selling Risperdal Consta in Canada on September 21, 2004.

Risperdal Consta is a new formulation of an existing compound (risperidone) indicated for the management of the manifestations of schizophrenia and related psychotic disorders.

Persons wishing to intervene in the proceeding are required to apply to the Board for leave to intervene **on or before February 27, 2006**. Such persons should contact the Secretary of the Board for further information on the procedure.

The Notice of Hearing in this matter and Board Staff's Statement of Allegations are available on the PMPRB Web site under Publications, Hearings.

All requests for information should be addressed to the Secretary of the Board.

Sylvie Dupont
Secretary of the Patented Medicine Prices Review Board

Toll-free number: 1-877-861-2350
Direct line: (613) 954-8299
Fax: (613) 952-7626
E-mail: sdupont@pmprb-cepmb.gc.ca
Web site: www.pmprb-cepmb.gc.ca

www.pmprb-cepmb.gc.ca